References
- Nicolle LE, Evans G, Laverdieve M, Phillips P, Quan C, Rotstein C. Complicated urinary tract infection in adults. Can J Infect Dis Med Microbiol. 2005;16:349–60.
- Hooton TM. Urinary tract infections in adults. N Engl J Med. 2012;366:1028–37.10.1056/NEJMcp1104429
- Oteoa J, Perez-Vazquez M, Campos J. Extended-spectrum B-lactamase producing Escherichia coli: changing epidemiology and clinical impact. Curr Opin Infect Dis. 2010;23:320–6.10.1097/QCO.0b013e3283398dc1
- Mody RM, Erwin DP, Summers AM, Carrero HA, Selby EB, Ewell EB, et al. Ertapenem susceptibility of extended-spectrum beta-lactamase-producing organisms. Ann Clin Microbiol Antimicrob. 2007;6:6–10.10.1186/1476-0711-6-6
- Fong JJ, Rosé L, Radigan EA. Clinical outcomes with Ertapenem as a first-line treatment option of infections caused by extended-spectrum β-lactamase producing Gram-negative bacteria. Ann Pharmacother. 2012;46:347–52.10.1345/aph.1Q473
- Zhou J, Sulaiman Z, Llorin R, Hee K-H, Lee L, Lye D, Fisher D, Tam V. Pharmacokinetics of ertapenem in outpatients with complicated urinary tract infections. J Antimicrob Chemother. 2014;69:2517–2521.
- Tomera KM, Burdmann EA, Reyna OG, Jiang Q, Wimmer WM, Woods GL, et al. Ertapenem versus Ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study. Antimicrob Agents Chemother. 2002;46:2895–2900.10.1128/AAC.46.9.2895-2900.2002
- Bazaz R, Champan ALN, Winstanley TG. Ertapenem administered as outpatient parenteral antibiotic therapy for urinary tracet infections caused by extended-spectrum-B-lactamase-producing Gram-negative organisms. J Antimicrob Chemother. 2010;65:1510–13.10.1093/jac/dkq152
- Song S, Kim C, Lim D. Clinical efficacy of Ertapenem for recurrent cystitis caused by multi-drug-resistant extended-spectrum B-lactamase-producing Eschericia coli in female outpatients. Korean J Urol. 2014;55:270–275.10.4111/kju.2014.55.4.270
- Qureshi ZA, Syed A, Doi Y. Safety and efficacy of long-term outpatient ertapenem therapy. Antimicrob Agents Chemother. 2014;58:3437–40.10.1128/AAC.02721-14
- Fisher DA, Kurup A, Lye D, Tambyah PA, Sulaiman Z, Poon EYH, Lee W, et al. Outpatient parenteral antibiotic therapy in Singapore. Int J Antimicrob Agents. 2006;28:545–550.10.1016/j.ijantimicag.2006.08.018
- Rubin RH, Shapiro ED, Andriole VT, Davis RJ, Stamm WE. General guidelines for the evaluation of anti-infective drugs for the treatment of urinary tract infection. Clin Infect Dis. 1992;15(Supplement 1):S216–S227.10.1093/clind/15.Supplement_1.S216
- Lye DC, Wijaya L, Chan J, Teng CP, Leo YS. Ertapenem for treatment of extended-spectrum beta-lactamase producing multidrug-resistant gram-negative bacteraemia. Ann Acad Med Sing. 2008;37:831–4.
- Wu UI, Chen WC, Yang CS, Wang JL, Hu FC, Chang SC, et al. Ertapenem in the treatment of bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli: a propensity score analysis. Int J Infect Dis. 2012;16:e47–e52.10.1016/j.ijid.2011.09.019
- Collins V, Marchaim D, Pogue JM, Moshos J, Bheemreddy S, Sunkara B, et al. Efficacy of Ertapenem for treatment of blood stream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2012;56:2173–7.10.1128/AAC.05913-11
- Dalgic N, Sancar M, Bayraktar B, Dincer E, Pelit S. Ertapenem for the treatment of urinary tract infections caused by extended-spectrum beta-lactamase-producing bacteria in children. Scand J Infect Dis. 2011;43:339–343.10.3109/00365548.2011.553241